Bladder Cancer
KEYPAD
This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).
Trial overview
Topic
Metastatic kidney cancer
Description
Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) KidnEY cancer Pembrolizumab And Denosumab.
Eligibility criteria
- Kidney Cancer after progression on first line treatment
- No prior treatment with immunotherapy
Study details
The treatment is 3 weekly Pembrolizumab and Denosumab. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
Further information
For more information regarding this clinical trial click here.
Location